Epoxyeicosatrienoic acids mediate adenosine-induced vasodilation in rat preglomerular microvessels (PGMV) via A2A receptors

Br J Pharmacol. 2004 Feb;141(3):441-8. doi: 10.1038/sj.bjp.0705640. Epub 2004 Jan 12.

Abstract

Activation of rat adenosine2A receptors (A2A R) dilates preglomerular microvessels (PGMV), an effect mediated by epoxyeicosatrienoic acids (EETs). Incubation of PGMV with a selective A2A R agonist, 2-p-(2-carboxyethyl) phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680; 100 microM), increased isolated PGMV EET levels to 7.57+/-1.53 ng mg-1 protein from 1.06+/-0.22 ng mg-1 protein in controls (P<0.05), without affecting hydroxyeicosatetraenoic acid (HETE) levels (10.8+/-0.69 vs 11.02+/-0.74 ng mg-1 protein). CGS 21680-stimulated EETs was abolished by preincubation with an A2A R antagonist, 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385) (100 microM). A selective epoxygenase inhibitor, methylsulfonyl-propargyloxyphenylhexanamide (MS-PPOH; 12 microM) prevented CGS 21680-induced increase in EETs, indicating inhibition of de novo synthesis of EETs. In pressurized (80 mmHg) renal arcuate arteries (110-130 microm) preconstricted with phenylephrine (20 nM), superfusion with CGS 21680 (0.01-10 microM) increased the internal diameter (i.d.) concentration-dependently; vasodilation was independent of nitric oxide and cyclooxygenase activity. CGS 21680 (10 microM) increased i.d. by 32+/-6 microm; vasodilation was prevented by inhibition of EET synthesis with MS-PPOH. Addition of 3 nM 5,6-EET, 8,9-EET and 11,12-EET increased i.d. by 53+/-9, 17+/-4 and 53+/-5 microm, respectively, whereas 14,15-EET was inactive. The responses to 5,6-EET were, however, significantly inhibited by indomethacin. We conclude that 11,12-EET is the likely mediator of A2A R-induced dilation of rat PGMV. Activation of A2A R coupled to de novo EET stimulation may represent an important mechanism in regulating preglomerular microvascular tone. British Journal of Pharmacology (2004) 141, 441-448. doi:10.1038/sj.bjp.0705640

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 8,11,14-Eicosatrienoic Acid / analogs & derivatives*
  • 8,11,14-Eicosatrienoic Acid / pharmacology
  • Adenosine / pharmacology*
  • Adenosine A2 Receptor Agonists
  • Animals
  • Arachidonic Acids / pharmacology*
  • Cytochrome P-450 CYP2J2
  • Cytochrome P-450 Enzyme System / pharmacology
  • Epoxy Compounds / pharmacology
  • Glomerular Mesangium / blood supply
  • Glomerular Mesangium / drug effects*
  • Male
  • Microcirculation / drug effects
  • Microcirculation / physiology
  • Oxygenases / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Adenosine A2A / physiology*
  • Renal Artery / drug effects
  • Renal Artery / physiology
  • Vasodilation / drug effects*
  • Vasodilation / physiology

Substances

  • Adenosine A2 Receptor Agonists
  • Arachidonic Acids
  • Epoxy Compounds
  • Receptor, Adenosine A2A
  • 11,12-epoxy-5,8,14-eicosatrienoic acid
  • Cytochrome P-450 Enzyme System
  • Oxygenases
  • Cytochrome P-450 CYP2J2
  • 8,11,14-Eicosatrienoic Acid
  • Adenosine